K
Klaus Lechner
Researcher at University of Vienna
Publications - 411
Citations - 18216
Klaus Lechner is an academic researcher from University of Vienna. The author has contributed to research in topics: Leukemia & Myeloid leukemia. The author has an hindex of 73, co-authored 411 publications receiving 17757 citations. Previous affiliations of Klaus Lechner include Boston Children's Hospital & University of Amsterdam.
Papers
More filters
Journal ArticleDOI
High plasma levels of factor viii and the risk of recurrent venous thromboembolism
Paul A. Kyrle,Erich Minar,Mirko Hirschl,Christine Bialonczyk,Milena Stain,Barbara Schneider,Ansgar Weltermann,Wolfgang Speiser,Klaus Lechner,Sabine Eichinger +9 more
TL;DR: Patients with a high plasma level of factor VIII have an increased risk of recurrent venous thromboembolism, and the likelihood of recurrence at two years was higher than among patients with lower levels.
Journal ArticleDOI
Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture.
Peter Valent,E. Spanblöchl,Wolfgang R. Sperr,Christian Sillaber,Krisztina M. Zsebo,Hermine Agis,Herbert Strobl,Klaus Geissler,Peter Bettelheim,Klaus Lechner +9 more
TL;DR: Observations suggest that rhSCF induces in vitro differentiation of human MCs from their BM and PB precursor cells in long-term culture and upregulates MC releasability.
Journal ArticleDOI
MDR1 Gene Expression and Treatment Outcome in Acute Myeloid Leukemia
Robert Pirker,Josef Wallner,Klaus Geissler,Werner Linkesch,Oskar A. Haas,Peter Bettelheim,Martina Hopfner,R. Scherrer,Peter Valent,Liselotte Havelec,Heinz Ludwig,Klaus Lechner +11 more
TL;DR: The data indicate that MDR1 gene expression is an unfavorable prognostic factor and suggest that multidrug resistance is important in AML.
Journal ArticleDOI
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Filgrastim in Remission Induction and Consolidation Therapy for Adults With De Novo Acute Myeloid Leukemia
Gerhard Heil,Dieter Hoelzer,Miguel A. Sanz,Klaus Lechner,John A. Liu Yin,Giuseppe Papa,Luc Noens,Jeff Szer,Arnold Ganser,Caroline O'Brien,J Matcham,Alan Barge +11 more
TL;DR: In conclusion, filgrastim is safe in that it had no negative impact on the prognosis of the AML patients and effectively reduced the duration of neutropenia, leading to significant clinical benefits by reducing theduration of fever; requirement for parenteral anti-infectives, specifically amphotericin B; and theurations of hospitalization.
Journal ArticleDOI
Hyperhomocysteinemia Is a Risk Factor of Recurrent Venous Thromboembolism
S. Eichinger,Andreas Stümpflen,Mirko Hirschl,Christine Bialonczyk,Kurt R. Herkner,Milena Stain,Barbara Schneider,Ingrid Pabinger,Klaus Lechner,Paul A. Kyrle +9 more
TL;DR: The high prevalence of hyperhomocysteinemia in thrombosis patients together with the increased risk of recurrence warrants extended patient screening and the impact on the risk ofRecurrence of prolonged anticoagulation, supplementation of folate and vitamin B12, or both have to be investigated.